Tag Archives: pharmaceutical industry

Drug middlemen illegally drive up the cost of insulin, FTC says, exposing a hidden layer of price manipulation in the pharmaceutical supply chain. These middlemen, who act as intermediaries between manufacturers and pharmacies, are accused of exploiting their position to inflate insulin prices, ultimately burdening patients and the healthcare system. …

Federal Trade Commission accuses three drug middlemen of inflating insulin prices sets the stage for this enthralling narrative, offering readers a glimpse into a story that is rich in detail and brimming with originality from the outset. The FTC alleges that these middlemen, who act as intermediaries in the pharmaceutical …

Ars Pharmaceuticals CEO sells over $1.29 million in company stock, raising eyebrows among investors and industry watchers alike. This significant transaction has sparked questions about the CEO’s confidence in the company’s future and the potential impact on the stock price. The sale comes at a time when Ars Pharmaceuticals is …

ARS Pharmaceuticals exec sells over .29 million in company stock – The news of an ARS Pharmaceuticals executive selling over $1.29 million in company stock has sent ripples through the financial world, prompting investors and analysts alike to scrutinize the implications of this significant transaction. This move, while seemingly routine, …

Ars Pharmaceuticals Exec Sells $140,000 in Company Stock, a move that has sent ripples through the financial world. This significant transaction, involving the sale of a substantial amount of company stock by a high-ranking executive, has sparked intense scrutiny and speculation. The timing of the sale, coupled with Ars Pharmaceuticals’ …

Rhythm Pharmaceuticals director Jennifer Good sells over $1.6m in stock, a move that has sparked curiosity and analysis within the pharmaceutical industry. This significant transaction raises questions about the company’s current financial standing and future prospects, especially in the context of its focus on developing treatments for rare diseases. Jennifer …

Neumora Therapeutics’ head of R&D sells over $490k in company stock, a move that has sent ripples through the pharmaceutical industry. This significant transaction raises questions about the company’s future prospects, the potential impact on investor sentiment, and the broader implications for research and development activities. The sale, which was …

Conduit Pharmaceuticals executive sells over $4.5 million in stock, a move that has sent ripples through the financial world. This significant transaction raises questions about the executive’s motivations, the potential impact on the company’s future, and the implications for investors. The sale, occurring amidst a backdrop of fluctuating market conditions …

BeiGene executive Wu Xiaobin sells over $1 million in company stock, a move that has sparked intrigue within the financial world. This transaction, occurring amidst a backdrop of fluctuating market conditions and recent company news, raises questions about potential motivations and implications for both BeiGene and the broader biotech industry. …

Recursion Pharmaceuticals director sells over $78k in company stock, sparking intrigue and raising questions about the company’s future trajectory. This move comes amidst a period of heightened scrutiny for the pharmaceutical industry, as investors grapple with the complexities of innovation and market volatility. The director’s decision to sell such a …